Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays

Vaccine. 2006 Feb 20;24(8):1087-94. doi: 10.1016/j.vaccine.2005.09.010. Epub 2005 Sep 19.

Abstract

We previously described antigen negative, provirus positive cats. Subsequently, we hypothesized that efficacious FeLV vaccines cannot prevent minimal viral replication. Thus, we vaccinated cats with either a canarypox-vectored live or a killed virus vaccine and analyzed the challenge outcome with quantitative PCR and a newly established real-time RT-PCR. When judged by conventional parameters (antigenaemia, virus isolation), most of the vaccinated cats were, as expected, protected from persistent viraemia. However, all cats were found to be plasma viral RNA positive. The loads were significantly associated with the infection outcome. Thus, commonly used FeLV vaccines understood to be successful model antiretroviral vaccines protecting against FeLV-related diseases do not confer sterilizing immunity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Cats
  • Enzyme-Linked Immunosorbent Assay
  • Leukemia Virus, Feline / immunology*
  • RNA, Viral / blood
  • Reverse Transcriptase Polymerase Chain Reaction
  • Vaccination
  • Viral Load
  • Viral Vaccines / immunology*
  • Viremia / prevention & control

Substances

  • Antibodies, Viral
  • RNA, Viral
  • Viral Vaccines